Literature DB >> 15378059

CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms.

Jonathan C Poe1, Yoko Fujimoto, Minoru Hasegawa, Karen M Haas, Ann S Miller, Isaac G Sanford, Cheryl B Bock, Manabu Fujimoto, Thomas F Tedder.   

Abstract

The interaction of CD22 with alpha2,6-linked sialic acid ligands has been widely proposed to regulate B lymphocyte function and migration. Here, we generated gene-targeted mice that express mutant CD22 molecules that do not interact with these ligands. CD22 ligand binding regulated the expression of cell surface CD22, immunoglobulin M and major histocompatibility complex class II on mature B cells, maintenance of the marginal zone B cell population, optimal B cell antigen receptor-induced proliferation, and B cell turnover rates. However, CD22 negative regulation of calcium mobilization after B cell antigen receptor ligation, CD22 phosphorylation, recruitment of SHP-1 to CD22 and B cell migration did not require CD22 ligand engagement. These observations resolve longstanding questions regarding the physiological importance of CD22 ligand binding in the regulation of B cell function in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15378059     DOI: 10.1038/ni1121

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  61 in total

1.  Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.

Authors:  Mayuka Horikawa; Veronique Minard-Colin; Takashi Matsushita; Thomas F Tedder
Journal:  J Clin Invest       Date:  2011-10-24       Impact factor: 14.808

2.  Differential roles of estrogen receptors α and β in control of B-cell maturation and selection.

Authors:  Latia Hill; Venkatesh Jeganathan; Prameladevi Chinnasamy; Christine Grimaldi; Betty Diamond
Journal:  Mol Med       Date:  2010-11-22       Impact factor: 6.354

3.  Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytoskeleton in restraining BCR signalling.

Authors:  Francesca Gasparrini; Christoph Feest; Andreas Bruckbauer; Pieta K Mattila; Jennifer Müller; Lars Nitschke; Dennis Bray; Facundo D Batista
Journal:  EMBO J       Date:  2015-12-15       Impact factor: 11.598

4.  CD22 and CD72 are inhibitory receptors dominantly expressed in B lymphocytes and regulate systemic autoimmune diseases : English version.

Authors:  T Tsubata
Journal:  Z Rheumatol       Date:  2017-03       Impact factor: 1.372

Review 5.  [CD22 and CD72 are inhibitory receptors dominantly expressed in B lymphocytes and regulate systemic autoimmune diseases. German version].

Authors:  T Tsubata
Journal:  Z Rheumatol       Date:  2016-02       Impact factor: 1.372

Review 6.  Rethinking mechanisms of autoimmune pathogenesis.

Authors:  Shiv Pillai
Journal:  J Autoimmun       Date:  2013-06-25       Impact factor: 7.094

Review 7.  Siglecs as sensors of self in innate and adaptive immune responses.

Authors:  James C Paulson; Matthew S Macauley; Norihito Kawasaki
Journal:  Ann N Y Acad Sci       Date:  2012-01-30       Impact factor: 5.691

Review 8.  Antibody-based therapies in patients with acute lymphoblastic leukemia.

Authors:  Shira Dinner; Michaela Liedtke
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

9.  CD22 expression mediates the regulatory functions of peritoneal B-1a cells during the remission phase of contact hypersensitivity reactions.

Authors:  Hiroko Nakashima; Yasuhito Hamaguchi; Rei Watanabe; Nobuko Ishiura; Yoshihiro Kuwano; Hitoshi Okochi; Yoshimasa Takahashi; Kunihiko Tamaki; Shinichi Sato; Thomas F Tedder; Manabu Fujimoto
Journal:  J Immunol       Date:  2010-03-24       Impact factor: 5.422

Review 10.  Basic and clinical immunology of Siglecs.

Authors:  Stephan von Gunten; Bruce S Bochner
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.